Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw unusually large options trading activity on Tuesday. Investors acquired 2,660 put options on the stock. This is an increase of 2,318% compared to the average daily volume of 110 put options.
In other news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 27th. The shares were sold at an average price of $8.00, for a total value of $160,000.00. Following the transaction, the chief financial officer now directly owns 330,815 shares in the company, valued at approximately $2,646,520. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Richard Anzalone sold 300,000 shares of the firm’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the transaction, the chief executive officer now owns 2,194,789 shares in the company, valued at $16,307,282.27. The disclosure for this sale can be found here. Over the last three months, insiders have sold 465,000 shares of company stock valued at $3,432,350. 4.60% of the stock is owned by company insiders.
Get Arrowhead Pharmaceuticals alerts:
Large investors have recently modified their holdings of the stock. Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at about $100,000. Vanguard Capital Wealth Advisors bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $119,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $123,000. Jane Street Group LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $130,000. Finally, Trexquant Investment LP bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at about $139,000. Hedge funds and other institutional investors own 28.50% of the company’s stock.
A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. B. Riley raised their price target on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Monday, February 12th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th. Finally, Piper Jaffray raised their price target on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Arrowhead Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $9.00.
Shares of NASDAQ:ARWR opened at $9.60 on Wednesday. Arrowhead Pharmaceuticals has a fifty-two week low of $9.21 and a fifty-two week high of $9.74. The company has a current ratio of 10.16, a quick ratio of 10.16 and a debt-to-equity ratio of 0.02.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. research analysts anticipate that Arrowhead Pharmaceuticals will post -0.73 earnings per share for the current year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.